Sephin1 found to protect oligodendrocytes, axons, and myelin, as well as reduce central nervous system inflammation in multiple sclerosis.
The economics of one and done gene therapies dictate a revenue model that requires outcomes-based risk.
The supplemental Biologics License Application was filed based on positive overall survival data from a phase 3 clinical trial for pembrolizumab in the treatment of recurrent or metastatic head and neck squamous cell carcinoma.
There are currently no FDA-approved therapies for the prevention or treatment of acute graft-versus-host disease.
Immunotherapy may become a viable option for patients with cancer infected with HIV.
Top news of the day across the health care landscape.
Analysis finds universal screening for hepatitis C virus infection would be cost effective and provide greater benefit than the currently recommended birth cohort screening.

Most Popular

Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.